Skip navigation
>»
RSS feed for this page
Know something we don't? Submit a conference announcement
Choose Category:

Infectious Diseases meetings & conferences

33 meetings & conferences listed in Infectious Diseases 

25th European Congress of Clinical Microbiology and Infectious Diseases
Denmark
04/25/2015

25th European Congress of Clinical Microbiology and Infectious Diseases

April 25-28, 2015 Copenhagen, Denmark

The 25th European Congress of Clinical Microbiology and Infectious Diseases will be held in Copenhagen, Denmark. The steady growth in importance of ECCMID has made it our mission to maintain or even increase the excellence of this congress. To achieve this goal the Program Committee will prepare a series of keynote lectures, symposium, educational workshops and meet-the-expert sessions on parallel tracks, covering the entire field of infectious diseases and clinical microbiology.

Microbiologist, Physician Researcher, Public Health Expert, Public Health Worker
HIV Vaccines
Canada
03/22/2015

HIV Vaccines

Joint with the meeting on The Golden Anniversary of B Cell Discovery

March 22—27, 2015 Banff, Alberta, Canada

Registered attendees of one meeting in a joint pair may participate in sessions of the other, pending space availability.

As the 30th anniversary of the discovery of HIV has come and gone, HIV remains a catastrophic public health concern, with an estimated global prevalence of 34 million HIV-infected persons. Despite the remarkable advances in the development of several biomedical interventions for the prevention of HIV, the importance of developing an effective HIV vaccine has been recognized by a wide spectrum of the scientific community and civil society. Important milestones for the HIV vaccine field were the demonstration that a vaccine regimen could reduce HIV acquisition and the identification of binding IgG envelope (env) antibodies as potential correlates of protection from HIV acquisition. However, broad neutralizing antibodies (bNAbs) are thought to be the main mechanism of protection of the currently available effective vaccines. The present meeting will address the major scientific gaps in the the generation of env bNAbs. The major goals of the meeting include: 1) To understand the development of bNAbs in natural infections and following vaccination; 2) To determine predictors of response to vaccines; 3) To review the advances in envelope immunogen design; 4) The therapeutic use of bNAbs; 5) The application of novel technologies to monitor the immune response; and 6) The development of therapeutic strategies aimed to functional HIV cure. The meeting will bring together interdisciplinary groups with outstanding expertise in B- and T-cell biology, structural biology, vaccinology and clinical science. It will therefore provide to the attendees how innovative basic observations from the bench side may translate into the clinical development of vaccines and therapeutic interventions.

Physician Researcher, Virologist
Co-Infection: A Global Challenge for Disease Control
Brazil
03/15/2015

Co-Infection: A Global Challenge for Disease Control

March 15—20, 2015 Ouro Preto, MG, Brazil

Organized in collaboration with the Minas Gerais State Agency for Research Development (FAPEMIG) and the National Council for Scientific and Technological Development (CNPq) - Brazil. Part of the Keystone Symposia Global Health Series, supported by the Bill & Melinda Gates Foundation

Multi-species co-infections impose one of the greatest challenges to global health and to our efforts to develop effective methods of infectious disease control. Populations living in rural areas of many low-income countries are exposed to both chronic and acute infection with multiple pathogens. In such conditions co-infection is common and the cause of additive or synergistic morbidities. Studying co-infections is difficult and complex as different pathogens may interact in many different ways, either directly or via the host immune response. Indeed, in some contexts, a community of organisms within a host may promote defense against other organisms. This Keystone Symposia meeting will focus on our current understanding of synergism/antagonism among pathogens causing common co-infections. In doing so it will bring together leading researchers and their knowledge of immune responses in co-infected individuals, co-infection immunoepidemiology, modeling of co-infections to predict disease and infection outcomes, and the specific challenges that co-infection presents to vaccine design strategies, and effective application of chemotherapy. This diversity of scientific disciplines will together address the impacts of co-infection, particularly in the context of the Neglected Tropical Diseases that are prevalent in many low- and middle-income countries. For example, in some of the poorest parts of the world, HIV, TB, leprosy, HTLV, malaria, dengue, and chronic helminth infections are co-endemic. To find the understanding and the means to effectively tackle the diverse clinical and public health problems of co-infection, we need to combine information derived from basic hypothesis-lead research, descriptive epidemiology and new computational modeling techniques. The goal of this symposium will be to broaden and deepen our understanding of within-host and population level interactions between different co-infecting pathogens and propose appropriate multidisciplinary strategies to move towards clinical and public health solutions, including the delivery of effective vaccination and chemotherapy.

Epidemiologist, Physician Researcher, Public Health Expert, Public Health Worker, Public Servant, Virologist
Dendritic Cells and Macrophages Reunited
Canada
03/08/2015

Dendritic Cells and Macrophages Reunited

March 8—13, 2015 Montreal, QC, Canada

The fields of macrophage and dendritic cell biology diverged decades ago and have evolved in a relatively independent fashion. In particular, DC meetings are devoting considerable attention to adaptive immune responses while macrophage meetings focus on innate immunity. Yet, it is clear that both cell types share many common properties and eventually contribute to a protective immunity. We therefore propose a meeting that aims to reunite the two communities of scientists. This meeting will be equally divided into basic biology and sessions dedicated to the importance of these cells in pathology including allergy, autoimmunity, cancer and infectious disease. We will emphasize human diseases as we would like this meeting to educate physician-scientists, both trained and in training.

Allergist, Cell Biologist, Immunologist, Molecular Biologist, Oncologist, Physician Researcher, Rheumatologist
Antibodies as Drugs: Immunological Scaffolds as Therapeutics
Canada
02/08/2015

Antibodies as Drugs: Immunological Scaffolds as Therapeutics

Joint with the meeting on Tumor Immunology: Multidisciplinary Science Driving Combination Therapy

February 8—13, 2015 Banff, Alberta, Canada

Registered attendees of one meeting in a joint pair may participate in sessions of the other, pending space availability.

While monoclonal antibodies are now an established class of drugs in oncology and inflammation, exciting progress has been recently made on next generation, engineered therapeutic antibodies and alternative immunological scaffolds, with first examples from this class being recently approved by FDA and EMA. The symposium will review progress in this area including lessons learned in the clinic and how this can be applied to new targets and drug candidates. It will cover major areas of activity including: 1) Increasing antibody potency via antibody engineering, better engaging immune effector cells, and improvements in targeted delivery of effectors via fusion proteins and via conjugation of cytotoxic drugs; 2) Applying alternative targeting approaches to increase the therapeutic window, such as pre-targeting and site-specific antibody unmasking; 3) Novel antibodies in areas outside of oncology, including infectious diseases, neurology and chronic inflammation; 4) Engineering antibodies and scaffolds for alternative delivery routes and improved disposition; 5) Clinical progress with multi-specific antibodies; and 6) Recent advances on (i) addressing difficult targets such as GPCRs and ion channels, (ii) alternative immunological scaffolds, and (iii) novel antibody library technologies.

Immunologist, Pharmacologist, Physician Researcher
Impact of Environmental Changes on Infectious Diseases
Spain
03/23/2015

Impact of Environmental Changes on Infectious Diseases

23-25 March 2015, Sitges, Spain

Environmental changes — the manifestations of which can include loss of biodiversity and habitat, increasing atmospheric temperature, rising sea level, and climatic instability (e.g., longer and more severe periods of drought or rainfall) — are likely to affect the prevalence of various infectious diseases by making conditions more (or less) propitious for the survival of pathogens and their vectors, and by inducing mass movement of human and animal populations.

This conference will discuss the impact of current and predicted future environmental changes on infectious disease dynamics in people, wildlife, and livestock across the globe, and what actions need to be taken.

Major themes for the conference include:

• The effects of climate changes, globalization, urbanization and habitat loss on infectious disease patterns in human and animal populations.

• Socio-demographic and economic factors influencing populations and their impact on the distribution and prevalence of infectious diseases.

• Policies and mechanisms of intervention to prevent or reduce the spread of infectious diseases related to environmental change.

• Future prospects for tackling emerging and neglected diseases.

Join us on March 23 to 25, 2015 in Sitges, Spain to discuss the latest evidence on how environmental changes are impacting the distribution and prevalence of infectious diseases

Physician Researcher, Policy Analyst, Public Health Expert, Public Health Worker, Public Servant, Scientist, Veterinary Scientist
Host Response in Tuberculosis
United States
New Mexico
01/22/2015

Host Response in Tuberculosis

Joint with the meeting on Granulomas in Infectious and Non-Infectious Diseases

January 22—27, 2015 Santa Fe, New Mexico

Part of the Keystone Symposia Global Health Series, supported by the Bill & Melinda Gates Foundation

Registered attendees of one meeting in a joint pair may participate in sessions of the other, pending space availability.

Tuberculosis remains a major cause of morbidity and mortality globally. Control of the epidemic is hampered by limited understanding of basic processes underlying disease and protection. This symposium will focus on this basic science in humans. Our themes will include immune processes that have emerged as important for pathogenesis or protection, rather than focusing on classical compartments of the immune system. Translation of basic science advances into novel strategies to prevent and manage human tuberculosis will also be discussed. Animal models have been critical for advancing knowledge of tuberculosis pathogenesis and control. This preclinical progress will be discussed; however, we will require an emphasis of direct relevance to human tuberculosis in each presentation. The meeting will be held jointly with one on Granulomas in Infectious and Non-Infectious Diseases, which is also the pathologic hallmark of tuberculosis. This will provide an opportunity for learning about other granulomatous systems, particularly how this knowledge may be applied for progress in understanding tuberculosis. Our brief specific aims for this meeting are: 1) Present and discuss cutting edge tuberculosis research on host responses; 2) Foster a better understanding of human tuberculosis, even if animal models are used; and 3) Focus on gaps in knowledge about the events in natural infection, as well as vulnerability points for intervening in the infection process.

Physician Researcher
Immunity to Veterinary Pathogens: Informing Vaccine Development
United States
Colorado
01/20/2015

Immunity to Veterinary Pathogens: Informing Vaccine Development

January 20—25, 2015 Keystone, Colorado

The need for more effective vaccines to protect food animals against infectious diseases has never been greater. Pressures on food sources are predicted to reach a critical state in a few decades resulting in food shortages, especially in the developing world. While there is a long history of using vaccination to control animal diseases, the most notable success being the eradication of rinderpest, there are many important diseases for which no effective vaccines are available. Advances in genomic technologies, coupled with improved knowledge of the cellular and molecular events involved in the immune response, provide exciting new opportunities for vaccine development. However, effective exploitation of these advances needs to be based on an understanding of the immune responses that mediate effective immunity against the target pathogens. While laboratory animal models have proved invaluable in elucidating fundamental immunological principles, the results of vaccination studies have often failed to translate to larger animal species and humans. Hence, there is a need to study the target diseases in their natural hosts. Animals also provide valuable experimental models for studies of zoonotic pathogens that cause disease in both animals and humans (e.g. TB and influenza), as well as closely related pathogens that cause similar diseases in animals and humans. This meeting seeks to highlight the value of studying immune responses to infectious disease in animals not only to develop control measures for animal diseases but also to advance knowledge that may be more widely applicable for vaccine development. Understanding the immune response in veterinary species holds the promise of accelerating vaccine development for food animals, companion pets and clearly humans, directly addressing the One World, One Health concept emerging in vaccine research.

Veterinary Scientist, Virologist
Granulomas in Infectious and Non-Infectious Diseases
United States
New Mexico
01/22/2015

Granulomas in Infectious and Non-Infectious Diseases

Joint with the meeting on Host Response in Tuberculosis

January 22—27, 2015 Santa Fe, New Mexico

This meeting will address the basic mechanisms of granulomatous inflammation and will focus on several chronic inflammatory diseases in which persistent granuloma formation is the central pathogenic mechanism of disease. The meeting will run in parallel another on Host Response in Tuberculosis, and will include two joint plenary sessions where both audiences will meet together. Granulomas form when the immune system attempts to wall off substances that it perceives as foreign but is unable to eliminate. These substances include infectious organisms such as bacteria and fungi as well as other known foreign materials. In some cases however, the offending antigen is unknown as in sarcoidosis. A granuloma is therefore a special type of inflammation, typically an organized collection of macrophages that occurs in a wide variety of infectious and non-infectious diseases including schistosomiasis, histoplasmosis, cryptococcosis, Crohn’s disease, sarcoidosis, and rheumatoid arthritis. The goal of this Keystone Symposia meeting on Granulomas in Infectious and Non-Infectious Diseases is to bring together researchers, clinicians, and members of the pharmaceutical industry to discuss the basic mechanics of granuloma formation, elucidate common pathogenic mechanisms, and identify novel areas of therapeutic intervention for the large number of chronic granulomatous diseases.

Physician Researcher
33rd Annual Meeting of the European Society for Paediatric Infectious Diseases
Germany
05/12/2015

33rd Annual Meeting of the European Society for Paediatric Infectious Diseases

May 12-15, 2015 Leipzig, Germany

Join 3,000 clinicians, researchers, residents, and students who come togethe​r each year for the Annual Meeting of the European Society for Paediatric Infectious Diseases. This year, our 33rd annual meeting (ESPID 2015) will be held on May 12-15 in dynamic Leipzig, Germany.

ESPID 2015’s scientific programme will consist of a range of sessions and learning opportunities, given by some of the top experts on Paediatric Infectious Diseases. Come discover the latest developments in our fast-changing world in Leipzig in 2015.​​​

Epidemiologist, Pediatrician, Pharmacologist, Physician, Physician Researcher, Virologist

prev134next